A recent study indicates that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt traditional diet and exercise programs.
Research printed in a major medical journal points out that while overweight individuals often shed substantial amounts of their body weight while using the jabs, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Individuals buying such treatments must be aware of the danger of quick rebound weight gain when the therapy is stopped," warns expert Dr. Susan Jebb.
That rate of recovery implies a return to starting mass in about 18 months.
Comparing Approaches
The study, which looked at 37 of studies involving over 9,000 of patients, compared the effects of these new drugs with other pills.
The team emphasize that individuals who lose weight through diet and exercise typically have a less rapid creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Rapid Rebound
Nutrition scientists propose the way of the jabs is key to understanding the accelerated rebound.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone levels several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making overeating far more likely."
A Lifelong Condition?
Medical guidelines suggest the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians say that, due to the likelihood of relapse, the treatment is often long-term.
This opinion is echoed by pharmaceutical companies, who state that the findings "highlight the persistent nature of obesity," similar to managing conditions like high blood pressure.
User Accounts
People who have discontinued the medication report a sudden resurgence of cravings.
"It was like something flipping and I was suddenly extremely hungry," recalled an individual.
The struggle is worsened if patients have not established sustainable lifestyle or habit changes during treatment.
Significant Use
Figures show that a significant number of adults in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians caution that while these medications are powerful agents for shedding pounds, they are not a magic cure and long-term success likely depends on combined behavioural support.
